Aging clocks measure biological change but do not indicate whether that change improves tissue function or disease outcomes. The field must distinguish between biomarkers that correlate with aging and interventions that produce meaningful clinical benefit.
Key Points
- Biomarker movement alone does not demonstrate functional improvement
- Correlation between a marker and outcome differs from causation
- Tissue function, not assay readout, should validate aging interventions
Longevity Analysis
As molecular tools proliferate, the ability to detect subtle shifts in cellular and epigenetic states has outpaced evidence that these shifts translate to preserved organ function, delayed disease, or extended healthspan. Investors and researchers face a critical task: determining whether a measurable change in an aging clock reflects biology that matters to the person being treated. This distinction shapes which interventions merit development and funding. A biomarker that moves predictably but fails to restore tissue resilience, improve stress response capacity, or alter disease trajectory is measurement without medicine. Horvath's emphasis on function over fanfare reflects a maturing field that must now prove causality, not merely demonstrate correlation.
Original published by Longevity.Technology, by Eleanor Garth.